OncoNano Closes $11.7 Million Series A Financing
OncoNano Medicine, Inc., closed a $11.7 million Series A financing transaction arranged by Salem Partners, who also participated as a principal investor. The Series A funding supplements a $6 million grant previously received from the Cancer Prevention and Research Institute of Texas .
OncoNano uses pH variability, a robust biomarker, to detect and treat diseased tissue. By targeting pH, a clear delineation between diseased and healthy tissue can be digitized to develop a broad range of targeted applications.
The company plans to use the funding to support continued clinical development of a new class of pH-activated compounds that digitalize and exploit the variability of pH in disease indications such as cancer.